Profile data is unavailable for this security.
About the company
Citius Oncology, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on oncology products. Its LYMPHIR (denileukin diftitox-cxdl) is approved by United States Food and Drug Administration for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (a rare form of non-Hodgkin lymphoma) after at least one prior systemic therapy. LYMPHIR is a specially engineered IL-2- diphtheria toxin fusion protein made using recombinant DNA technology. It works by targeting cells that have IL-2 receptors with a toxin derived from diphtheria bacteria. It directly kills tumor cells by binding to the IL-2 receptors and internalizing the diphtheria toxin directly into the tumor cells, causing them to die. It boosts the body's immune response by reducing the number of regulatory T-cells (Tregs) that suppress the immune system, thereby enhancing the body's ability to fight the tumor.
- Revenue in USD (TTM)0.00
- Net income in USD1.93m
- Incorporated2024
- Employees--
- LocationCitius Oncology Inc420 Lexington Ave, Suite 2446NEW YORK 10017United StatesUSA
- Phone+1 (347) 627-0058
- Fax+1 (302) 531-3150
- Websitehttps://www.tenxkeane.com/
More ▼
Mergers & acquisitions
| Acquired company | CTOR:NAQ since announced | Transaction value |
|---|---|---|
| Citius Oncology Inc | -84.59% | 675.00m |
Data delayed at least 15 minutes, as of Sep 19 2024 20:59 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Relmada Therapeutics Inc | 0.00 | -86.76m | 105.31m | 20.00 | -- | 1.71 | -- | -- | -2.88 | -2.88 | 0.00 | 2.04 | 0.00 | -- | -- | 0.00 | -89.88 | -- | -100.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
| Regulus Therapeutics Inc | 0.00 | -35.39m | 106.05m | 31.00 | -- | 1.08 | -- | -- | -1.26 | -1.26 | 0.00 | 1.50 | 0.00 | -- | -- | 0.00 | -47.90 | -53.74 | -52.71 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.00 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
| Sagimet Biosciences Inc | 2.00m | -29.25m | 108.82m | 10.00 | -- | 0.5885 | -- | 54.41 | -1.18 | -1.18 | 0.078 | 5.74 | 0.019 | -- | -- | 200,000.00 | -27.79 | -- | -29.32 | -- | -- | -- | -1,462.55 | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
| Verastem Inc | 10.00m | -89.49m | 109.06m | 73.00 | -- | 3.86 | -- | 10.91 | -3.34 | -3.34 | 0.3726 | 1.49 | 0.0672 | -- | 2.00 | 136,986.30 | -60.16 | -62.70 | -72.65 | -75.18 | -- | -- | -894.91 | -406.17 | -- | -- | 0.5052 | -- | -100.00 | -- | -18.36 | -- | -- | -- |
| Annovis Bio Inc | 0.00 | -43.02m | 109.13m | 6.00 | -- | -- | -- | -- | -4.42 | -4.42 | 0.00 | -0.1494 | 0.00 | -- | -- | 0.00 | -308.78 | -106.31 | -395.89 | -124.71 | -- | -- | -- | -- | -- | -51.53 | -- | -- | -- | -- | -121.90 | -- | -- | -- |
| Leap Therapeutics Inc | 0.00 | -60.34m | 110.20m | 54.00 | -- | 1.68 | -- | -- | -2.00 | -2.00 | 0.00 | 1.72 | 0.00 | -- | -- | 0.00 | -67.81 | -80.06 | -80.19 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -17.69m | 110.30m | 9.00 | -- | 19.92 | -- | -- | -0.1726 | -0.1726 | 0.00 | 0.0537 | 0.00 | -- | -- | 0.00 | -91.52 | -58.16 | -138.98 | -75.36 | -- | -- | -- | -- | -- | -- | 0.0427 | -- | -- | -- | -14.90 | -- | -- | -- |
| Citius Oncology Inc | 0.00 | 1.93m | 110.52m | -- | 6.41 | 0.2236 | 57.16 | -- | 0.242 | 0.242 | 0.00 | 6.93 | 0.00 | -- | -- | -- | 3.25 | -- | 3.35 | -- | -- | -- | -- | -- | -- | -- | 0.036 | -- | -- | -- | 535.30 | -- | -- | -- |
| Checkpoint Therapeutics Inc | 78.00k | -42.47m | 110.74m | 23.00 | -- | -- | -- | 1,419.79 | -1.50 | -1.50 | 0.0027 | -0.372 | 0.0111 | -- | 2.17 | 3,391.30 | -606.33 | -142.43 | -- | -342.79 | -- | -- | -54,444.87 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
| Anixa Biosciences Inc | 0.00 | -12.36m | 111.02m | 4.00 | -- | 5.09 | -- | -- | -0.3906 | -0.3906 | 0.00 | 0.6772 | 0.00 | -- | -- | 0.00 | -50.54 | -59.69 | -52.50 | -62.61 | -- | -- | -- | -6,040.10 | -- | -- | 0.00 | -- | -- | -28.36 | 27.83 | -- | -- | -- |
| ALX Oncology Holdings Inc | 0.00 | -171.44m | 112.72m | 74.00 | -- | 0.7046 | -- | -- | -3.64 | -3.64 | 0.00 | 3.04 | 0.00 | -- | -- | 0.00 | -74.45 | -34.34 | -84.76 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.0734 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
| PDS Biotechnology Corp | 0.00 | -40.68m | 113.04m | 25.00 | -- | 3.65 | -- | -- | -1.23 | -1.23 | 0.00 | 0.8406 | 0.00 | -- | -- | 0.00 | -65.48 | -51.63 | -80.82 | -59.00 | -- | -- | -- | -- | -- | -21.59 | 0.4409 | -- | -- | -- | -5.11 | -- | -- | -- |
| Fibrobiologics Inc | 0.00 | -19.47m | 113.92m | 10.00 | -- | -- | -- | -- | -0.939 | -0.939 | 0.00 | -0.073 | 0.00 | -- | -- | 0.00 | -171.13 | -- | -333.35 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -272.15 | -- | -- | -- |
| Cardiff Oncology Inc | 665.00k | -40.88m | 114.51m | 31.00 | -- | 2.14 | -- | 172.20 | -0.9142 | -0.9142 | 0.0149 | 1.15 | 0.0081 | -- | 2.17 | 21,451.61 | -49.98 | -31.24 | -57.60 | -33.56 | -- | -- | -6,143.91 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| INmune Bio Inc | 85.00k | -37.74m | 115.08m | 11.00 | -- | 2.76 | -- | 1,353.82 | -2.06 | -2.06 | 0.0046 | 1.88 | 0.0014 | -- | 0.0311 | 7,727.27 | -61.78 | -37.82 | -80.24 | -41.86 | -- | -- | -44,402.35 | -14,901.03 | -- | -23.01 | 0.1184 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
| Assembly Biosciences Inc | 21.48m | -45.61m | 115.30m | 65.00 | -- | 3.32 | -- | 5.37 | -9.32 | -9.32 | 4.28 | 5.47 | 0.2362 | -- | 125.62 | 330,476.90 | -50.15 | -39.69 | -69.22 | -44.03 | -- | -- | -212.33 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
Data as of Sep 19 2024. Currency figures normalised to Citius Oncology Inc's reporting currency: US Dollar USD
4.81%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| TD Securities (USA) LLCas of 30 Jun 2024 | 627.18k | 0.88% |
| W.R. Berkley Corp. (Investment Portfolio)as of 30 Jun 2024 | 530.50k | 0.74% |
| RiverNorth Capital Management LLCas of 30 Jun 2024 | 350.00k | 0.49% |
| Mizuho Securities USA LLCas of 30 Jun 2024 | 343.50k | 0.48% |
| Glazer Capital LLCas of 30 Jun 2024 | 306.72k | 0.43% |
| Westchester Capital Management LLCas of 30 Jun 2024 | 300.00k | 0.42% |
| Hudson Bay Capital Management LPas of 30 Jun 2024 | 299.30k | 0.42% |
| Logan Stone Capital LLCas of 30 Jun 2024 | 243.16k | 0.34% |
| Yakira Capital Management, Inc.as of 30 Jun 2024 | 225.00k | 0.32% |
| The Quarry LPas of 30 Jun 2024 | 200.20k | 0.28% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
